Time to Integrate Malaria and Neglected Tropical Diseases Control and Elimination
Dirk Engels,Fang Huang,Xiao-Nong Zhou
DOI: https://doi.org/10.46234/ccdcw2021.100
2021-01-01
China CDC Weekly
Abstract:Traditionally, malaria has always been considered one of the tropical diseases. This only has changed in the late 1990s, with the World Health Organization (WHO) profiling HIV, tuberculosis (TB), and malaria as priority “poverty-related” killing diseases (1). This has led to the creation of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (2), that has mobilized substantial resources to advance the control of all three diseases, even if mostly in a siloed manner. Around the same time, efforts were undertaken to solicit international attention for an entire group of other tropical diseases, currently still affecting over 1.7 billion people worldwide, that had been left “neglected” (3). The global response that was mounted to advance the control/elimination of neglected tropical diseases (NTDs) — that are more disabling than killing diseases — was based on a different logic. It profiled NTDs as a group of diseases that 1) together represented a similar burden as HIV, TB, or malaria; 2) were treatable or preventable by similar interventions that could be delivered as integrated packages; and 3) were entrenched in poverty as no other diseases, urging the international community to prioritize the deployment of development efforts focused on the poorest sections of society. Both global strategies have worked well, even though with vastly different levels of resources. Impressive global progress has been made in the fight against malaria over the last two decades. The malaria case incidence rate (cases per 1,000 population at risk) has decreased from 80 in 2000 to 57 in 2019, a reduction of almost 30%. The mortality incidence rate (deaths per 100,000 population at risk) was reduced from 25 in 2000 to 10 in 2019, or a reduction of 60%. As a result, the global number of deaths due to malaria has fallen from 736,000 in 2000 to 409,000 in 2019, a decrease of over 40%. Over the same period, the number of countries with fewer than 100 indigenous malaria cases increased from 6 to 27, with 21 countries — including China — reporting zero indigenous malaria cases for at least three consecutive years, and 10 of these countries being certified malariafree by the WHO (4). In 2019, an estimated 3.0 billion USD was spent globally on malaria control and elimination (5). Interventions for NTDs, especially large-scale preventive treatments for lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and trachoma, have scaled up massively over the last decade with over a billion people reached yearly from 2015 to 2019. This has led, at the end of 2020, to already 600 million fewer people needing interventions for NTDs and 42 countries having eliminated at least one NTD. A complex disease such as sleeping sickness has been brought to the verge of elimination, elimination of visceral leishmaniasis is close to being achieved in South-East Asia, and the global number of reported cases of Chagas disease has decreased by 40% between 2011 and 2019. During the same period, 90 million people have been freed from the risk of vector transmission of Chagas disease, and universal blood screening for the disease implemented at 100% in Latin-America (6–7). The yearly amount of Overseaos Development Aid (ODA) funding has been estimated to be in the order of 300 million USD per year since 2014, leveraging a contribution in medicines donated by the pharmaceutical sector with a value of approximately 1.5 billion USD per year (8–9). Despite good progress, both program areas face challenges. The global gains in combating malaria have levelled off in recent years. The emergence of resistance to insecticides and medicines is threatening malaria control and elimination (10), and the quest for novel technological solutions is hardly coping with the need. Redistributing resources toward control or eliminationspecific interventions, such as diagnosis and treatments, vector control, preventive treatments in pregnant women and children, and strengthening surveillance systems to identify and investigate foci, may produce economic efficiencies (5). Hence the increasing awareness that something more fundamentally preventive needs to be done, and new program and policy interventions to be developed, such as integrated vector management along with China CDC Weekly